MoBiTec GmbH

AUM LifeTech's Self-Delivering FANA Antisense Oligonucleotides to be Distributed by MoBiTec Germany

AUMsilence self-delivering oligos achieve highly efficient and potent antisense-based gene knockdown. No need to use toxic transfection reagents. Especially designed for primary cells and very difficult-to-transfect cell types.

Goettingen, Germany, September 24, 2016 --( Self-delivering FANA antisense oligonucleotide technology for basic, translational, and pre-clinical research.

Genes contain the instructions to build and maintain each and every living organism. Gene regulation is a highly controlled process. However, many diseases result from altered expression of one or more genes. AUM LifeTech is primarily working to identify and fix these anomalies and genetic disorders.

With the expanding advances in genetic regulatory networks researchers are now able to efficiently link diseases/disorders with certain genes. The advances in sequencing technologies have enabled scientists to make much more sense of this plethora of genetic information. This has enabled to further establish gene function that has the potential to treat and/or prevent human diseases.

Further, these advancements have created a huge demand for a technology that can be used to find research and clinical solutions using this genetic information. To this end, AUM LifeTech aims to develop innovative, potent, and cost effective genomics solutions in the area of basic biomedical research, clinical diagnostics, and therapeutics.

Transition of short interfering RNAs (siRNAs) and antisense oligonucleotides (AONs) from the bench to the bedside has thus far faced a number of challenges, the most significant of which include target accessibility, specificity, poor extracellular/
intracellular stability, toxicity, and effective delivery into target cells. AUM LifeTech's next generation 2'F-ANA chemistry – a 2′-deoxy-2′-fluoro-beta-D-arabinose sugar chemistry – can provide a potent, stable, efficient, and cost-effective solution in the gene silencing-based discovery and therapeutic space.

AUM LifeTech has exclusive license(s) on key aspects of 2′-deoxy-2′-fluoro-beta-D-arabinonucleic acid (FANA) technology from McGill University, Canada.


1) Gene Silencing / Knockdown

AUMsilence self-delivering oligos achieve highly efficient and potent antisense-based gene knockdown. No need to use toxic transfection regents. Especially designed for primary cells and very difficult to transfect cell types. Ideal for animal studies. Suited for fish and amphibian model systems as well.

Highly recommended as a replacement for siRNAs or other oligonucleotide approaches.

2) microRNA Regulation and Modulation

AUMantagomir self-transfecting oligos serve as potent antagomirs by binding with miRNAs and prevent their hybridization with their target mRNAs.

AUMmirblocker self-transfecting oligos serve as competitive blockers/decoys against miRNAs to inhibit their binding with target mRNA.

AUMmirblocker oligos will bind with the targeted regions on the mRNA
and inhibit binding of miRNA with the mRNA.

3) Long non-coding RNA Regulation

AUMlnc oligos achieve potent RNase H-mediated cleavage of the target long non-coding RNA.

4) Exon Skipping

AUMskip oligos make suitable candidates for exon-skipping experiments.

5) Decoys, Blockers and Probes

AUMblock oligos act as steric blockers and inhibit translation elongation. AUMblock oligos act as decoys and repress protein expression and do not induce mRNA cleavage.

AUMprobes serve as excellent probes or decoys to suit a wide variety of experimental applications.

AUM LifeTech:

"At AUM we are taking initial steps towards development of personalized medicine at the genetic level. We are exploring creative approaches to develop the next generation of innovative genomics tools in the area of gene silencing and manipulation for biomedical research and therapeutic applications. Initially targeted for scientists and researchers seeking to understand biology and disease, these tools will eventually have applications in treating genetic disorders by development of Nucleic Acid based Therapeutics. Stay Tuned."


"We are thrilled about the opportunity to be able to offer AUM LifeTech's groundbreaking technology to our customers as being involved in international health is fundamental to MoBiTec," said Joerg Ronnenberg, CEO, MoBiTec GmbH, Germany.

All AUM LifeTech products can be ordered from MoBiTec as of now.
MoBiTec GmbH
Arne Schulz